Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia

Falini, Brunangelo; Martelli, Maria Paola

doi:10.1002/ajh.26812

Cited by 21 publications

(22 citation statements)

References 123 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The most common aggressive NHLs in Western countries are diffuse large B-cell lymphoma (DLBCL), Mantle Cell lymphoma (MCL) and Burkitt lymphoma, which account for 31, 6 and 2% of adult cases, respectively [6] . Owing to their unique genomic features, biological behavior and poor clinical prognosis, the subtypes of DLBCL, formerly known as double-hit (DHL) and triple-hit (THL) lymphomas, were classified in 2016 as a new category, termed "high-grade B-cell lymphoma" (HGBL), with translocations involving MYC and B-Cell Lymphoma 2 (BCL2) and/or B-Cell Lymphoma 6 (BCL6).…”

Section: High-grade B-cell Lymphomasmentioning

confidence: 99%

Targeting MYC-driven lymphoma: lessons learned and future directions

Martínez-Martín¹,

Beaulieu²,

Soucek³

2023

Cancer Drug Resist

View full text Add to dashboard Cite

MYC plays a central role in tumorigenesis by orchestrating cell proliferation, growth and survival, among other transformation mechanisms. In particular, MYC has often been associated with lymphomagenesis. In fact, MYC overexpressing lymphomas such as high-grade B-cell lymphoma (HGBL) and double expressor diffuse large B-cell lymphomas (DLBCL), are considered addicted to MYC. In such a context, MYC targeting therapies are of special interest, as MYC withdrawal is expected to result in tumor regression. However, whether high MYC levels are always predictive of increased sensitivity to these approaches is not clear yet. Even though no MYC inhibitor has received regulatory approval to date, substantial efforts have been made to investigate avenues to render MYC a druggable target. Here, we summarize the different classes of molecules currently under development, which mostly target MYC indirectly in aggressive B-cell lymphomas, paying special attention to subtypes with MYC/BCL2 or BCL6 translocations or overexpression.

show abstract

Section: High-grade B-cell Lymphomasmentioning

confidence: 99%

Targeting MYC-driven lymphoma: lessons learned and future directions

Martínez-Martín¹,

Beaulieu²,

Soucek³

2023

Cancer Drug Resist

View full text Add to dashboard Cite

show abstract

“…16,35 The ICC and WHO 2022 guidelines classify AML with SF3B1 Mu (and without concurrent TP53 Mu ) as AML with myelodysplasia-related gene mutations or myelodysplasia-related AML, respectively. 3,16,33,35,36 In MDS, SF3B1 Mu is generally considered to be favorable, with longer OS (mOS 79 vs. 53 months), and lower rates of AML transformation (7% vs. 15%) compared to SF3B1 WT . 35 However, concomitant abnormalities of del(5q), RUNX1 Mu , TP53 Mu , and CK negatively impact outcomes.…”

Section: Dnmt3amentioning

confidence: 99%

“…TP53 alterations are present in about 13%–18% of AML and 7% of MDS cases, and are the best somatic mutation predictor of aggressive disease 36,40,41 . TP53 Mu is enriched in therapy‐related AML and MDS, and in malignancies with CK, monosomal karyotype (MK), and chromosomal abnormalities in −5/del(5q), −7/del(7q), and − 17, supporting the hypothesis that TP53 aberrations are indicative of severe genomic instability 40,42 .…”

Section: Introductionmentioning

confidence: 99%

Molecular findings in myeloid neoplasms

TRAN

Siddon

2023

Int J Lab Hematology

View full text Add to dashboard Cite

The proliferation of new molecular technologies in recent years has greatly advanced our knowledge of the genetics that underlie hematologic cancers. Particularly, with the advent and wide-implementation of next-generation sequencing (NGS), a host of somatic (and some germline) gene mutations have been identified as significant in the classification, prognostication, and treatment of the spectrum of myeloid neoplasms. These driver and disease modifier mutations now play a prominent role in the updated international diagnostic guidelines of acute myeloid leukemia (AML), myelodysplastic syndromes/neoplasms (MDS), and myeloproliferative neoplasms (MPN).As high-throughput technologies such as NGS increasingly become standard in the genetic evaluation of myeloid disorders, it is critical that clinicians understand the clinical relevance of these mutations in order to further personalize patient care. In this review we discuss some of the most essential somatic and cytogenetic findings.

show abstract

“…This led by necessity to the development of the International Consensus Classification (ICC) of myeloid neoplasms and acute leukemias as an alternative to the WHO fifth edition 1,2 . Falini and Martelli, in this issue of the American Journal of Hematology, 3 illustrate the similarities and differences in MDS and AML between the International Consensus Classification (ICC) 4 and what is currently proposed for the fifth edition WHO classification, 5 and compare them to the current revised fourth edition WHO classification 6 . While there are many similarities between the two new classifications (which is not unexpected when similar groups review similar literature), there are indeed differences which have also been highlighted elsewhere 7,8 .…”

mentioning

confidence: 99%

“…Finally, it should be noted that the Khoury et al manuscript 5 cited by Falini and Martelli 3 is an early version of the classification; there is also a slightly more detailed web version of the fifth edition WHO available for subscribers which is termed “beta version,” but no final published document is yet available and the classification draft put forth in the Khoury et al article and current online are still subject to change. In contrast, the ICC classification is published in its final form in the Arber et al article 4 .…”

mentioning

confidence: 99%

Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia

Arber

Orazi

2022

American J Hematol

View full text Add to dashboard Cite

The increase in our understanding of the genetic complexity of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well at the rapid introduction of more targeted therapies for these diseases has made the diagnosis and classification of AML and MDS more challenging and nuanced. The third, fourth, and revised fourth edition World Health Organization (WHO) classifications, published by the International Agency on Cancer (IARC), have succeeded in incorporating new genetic criteria in the various disease classification schemes by carefully handling the overwhelming amount of data and complexity of these disorders. Updating an existing classification system requires not only integrating the most recent published literature, but also developing a consensus by overcoming differences of opinion on how to incorporate the new data. The updating process was developed by the Society for Hematopathology and the European Association for Hematopathology through a Clinical Advisory Committee (CAC). The CAC met prior to each classification being developed, to come to a consensus on what to change and how to incorporate those changes into comprehensive diagnostic criteria. IARC also provided input and published the classification within their Blue Book series.

show abstract

Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia

Cited by 21 publications

References 123 publications

Targeting MYC-driven lymphoma: lessons learned and future directions

Targeting MYC-driven lymphoma: lessons learned and future directions

Molecular findings in myeloid neoplasms

Moving toward more molecular classifications of myelodysplastic syndrome and acute myeloid leukemia

Contact Info

Product

Resources

About